Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Ofman On Value-Based Contracts And Reimbursement Challenges

Jul 07 2017

• By Mandy Jackson

Customer Value concept on the gearwheels, 3D rendering

Related Content

Medicaid Drug Formulary Ideas Floated, But US Manufacturers Are Skeptical

Mar 02 2017

Amgen Faces New ICER Roadblock To Repatha Reimbursement

Jun 15 2017

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Mar 18 2017

Enbrel's First Outcomes Contract Is With Harvard Pilgrim; Others May Follow

Apr 07 2017

Patient Voice Needed In Outcomes-Based Contracts, PhRMA Exec Says

May 31 2017

Value-Based Contracts: Relief From Regulatory Barriers In Sight?

Feb 13 2017

Rx Pricing: Adversaries Search For Common Ground On Value-Based Contracts

Jun 21 2017

'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets

Dec 11 2012

Related Companies

Amgen, Inc.

University of Southern California

Additional Topics

Market Access Pricing Strategies Pricing Debate Biologics Commercial BioPharmaceutical

More from Drug Pricing

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window